Back to top
more

Cencora, Inc. (COR)

(Delayed Data from NYSE)

$278.40 USD

278.40
1,732,273

-5.38 (-1.90%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $278.29 -0.11 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

GE HealthCare (GEHC) AI Model to Predict Immunotherapy Response

by Zacks Equity Research

GE HealthCare (GEHC) announces statistics on AI models that collect clinical data to accurately predict the effectiveness and toxicity of cancer immunotherapy.

Zacks Equity Research

Cardinal Health (CAH) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

Zacks Equity Research

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Fresenius Medical (FMS) Divests Assets to Optimize Portfolio

by Zacks Equity Research

Fresenius Medical's (FMS) latest asset divestments reflect a milestone in its portfolio optimization program and are likely to improve profitability.

Zacks Equity Research

Medtronic's (MDT) MiniMed 780G System Study Data Favorable

by Zacks Equity Research

Medtronic's (MDT) data from a recent study indicate that the MiniMed 780G system exceeds international targets for TIR and even brings patients closer to euglycemia.

Zacks Equity Research

Reasons to Add The Cooper Companies (COO) to Your Portfolio Now

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Zacks Equity Research

Zimmer Biomet (ZBH) Rides on ROSA Uptake, Favorable Trend

by Zacks Equity Research

Focused execution of Zimmer Biomet's (ZBH) global sales teams amid a stable global musculoskeletal market helps accelerate global sales.

Zacks Equity Research

Labcorp (LH) Introduces Weight Loss Management Portfolio

by Zacks Equity Research

Labcorp's (LH) Weight Loss Management service includes proven tests from its extensive menu and simplifies the procedure for both physicians and patients.

Zacks Equity Research

Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.

Zacks Equity Research

Neuronetics (STIM) Progresses in MRD and TRD With New Deal

by Zacks Equity Research

The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.

Zacks Equity Research

DexCom's (DXCM) Direct-to-Watch Feature to Boost Its G7 System

by Zacks Equity Research

DexCom (DXCM) announces its direct-to-Apple-Watch feature for the G7 CGM system, which is likely to help people in better management of diabetes monitoring.

Zacks Equity Research

Stereotaxis (STXS) Seeks Clearance for MAGiC Catheter

by Zacks Equity Research

Stereotaxis (STXS) announces the regulatory submissions of its MAGiC catheter in Europe and the United States, which are intended for use in minimally invasive cardiac ablation treatments.

Zacks Equity Research

DexCom (DXCM) Soars 10% This Week: What's Fueling the Gain?

by Zacks Equity Research

A recent approval for DexCom's (DXCM) new CGM device boosts the prospects of the company by broadening the targeted market. Shares gain as investors see strong potential for growth going forward.

Zacks Equity Research

Here's Why You Should Retain Walgreens Boots (WBA) For Now

by Zacks Equity Research

Investors are optimistic about Walgreens Boots (WBA), led by its strategic partnerships and long-term growth model.

Zacks Equity Research

Abbott (ABT) to Reduce Childhood Malnutrition With New Pact

by Zacks Equity Research

Abbott's (ABT) latest partnership supports its sustainability goal of transforming care for malnutrition and improving the lives of 3 billion people per year by the decade's end.

Zacks Equity Research

QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis

by Zacks Equity Research

QuidelOrtho's (QDEL) receipt of Health Canada's approval is likely to aid in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women.

Zacks Equity Research

Reasons to Retain Inari Medical (NARI) in Your Portfolio Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.

Zacks Equity Research

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Zacks Equity Research

Silk Road Medical's (SILK) New Stent Expands Its TCAR Portfolio

by Zacks Equity Research

Silk Road Medical (SILK) announces the launch of its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States.

Zacks Equity Research

Should JPMorgan Diversified Return U.S. Equity ETF (JPUS) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JPUS

Zacks Equity Research

Hologic's (HOLX) BCI Genomic Test Study Outcome Favorable

by Zacks Equity Research

Hologic's (HOLX) BCI test is the only genomic test that is approved by various national oncology guidelines.

Zacks Equity Research

DaVita (DVA) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about DaVita's (DVA) strength in its kidney care.

Zacks Equity Research

DaVita (DVA) Expands Operational Footprint Via New Agreement

by Zacks Equity Research

DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America.

Zacks Equity Research

Stryker (SYK) Completes First Arthroplasty Surgery in Europe

by Zacks Equity Research

Stryker (SYK) completes its first shoulder arthroplasty surgery in Europe using its Blueprint Mixed Reality Guidance system, which aims to benefit shoulder arthroplasty surgeons.

Zacks Equity Research

DexCom's (DXCM) Stelo Glucose Biosensor Receives FDA Approval

by Zacks Equity Research

DexCom's (DXCM) Stelo receives FDA clearance, which makes it the first FDA-approved glucose biosensor to be available over the counter.